Last Updated: Monday, 11 May 2020, 10:13AM (NZDT)
1. There are currently no published clinical studies (as at May 2020) which demonstrate HME use reduces infection risk to clinicians when compared with heated humidification
2. Heated humidification reduces the need for circuit breaks and promotes a closed system, which reduces infection risk from cross-contamination
The use of a heated humidifier reduces the requirements for circuit breaks. Every circuit break increases the risk of cross-contamination or infection for clinicians treating COVID‑19 patients.
3. Heated humidification can reduce the occurrence of ETT obstructions from thickened secretions, which may reduce requirements for clinical intervention and aerosol exposure
Heated humidifiers can deliver higher levels of absolute humidity than HMEs.1,2 Delivery of inspired gas closer to core temperature and saturated (37 °C, 44 mg/L H2O) aids the optimal function of the mucociliary transport system. It reduces the risk of thickening or retention of secretions, which can lead to increased resistance to flow through ETTs, or ETT obstruction. The use of heated humidifiers has been associated with a better quality of airway secretions1 and a lower incidence of endotracheal tube obstruction when compared to HMEs.1,3–6 These effects may reduce the requirement for reintubation, and subsequently, the aerosol exposure of clinicians to infectious particles that are associated with performing intubation procedures.
4. Heated humidification generates water vapor (not aerosols) that cannot transport viruses or bacteria
Heated humidifiers represent an active form of humidification that warms respiratory gas within the humidification chamber and delivers water vapor particles to the patient.7,8 The process of vaporization generates a molecular distribution of water in the air that exerts a gaseous pressure. Due to the molecular nature of water distribution and the typical size of water vapor particles (~ 0.0001 microns), water vapor particles are too small to transport bacteria or viruses.9 Aerosolized water droplets can carry these pathogens and this is the reason why COVID‑19 clinical guidelines recommend infection control strategies for aerosol generating procedures such as intubation, nebulization, and bronchoscopy. The provision of heated humidification for invasive ventilation is not an aerosolizing procedure for invasively ventilated patients, as per COVID‑19 guidelines.10
5. Newer technology circuits can significantly reduce condensation compared to conventional heated humidifier circuits. Circuit breaks can be reduced, transmission risk decreased, and a closed system promoted
Newer technology circuits can significantly reduce condensation because the material allows water vapor to diffuse through the circuit wall. This material in F&P Evaqua 2 has been designed and tested to ensure that viruses and bacteria cannot permeate or diffuse through the material; only water vapor. F&P Evaqua 2 circuits have insulating material in the inspiratory limb to prevent gas from cooling and condensing in the circuit. The inspiratory insulation and expiratory water vapor diffusion lead to significantly less condensation compared with conventional heated humidifier circuits and reduce the need to break the circuit to empty condensate.
6. Clinicians can use the same invasive ventilation circuit for NIV and NHF on extubated patients; reducing the amount of contaminated waste to be handled
Using a heated humidifier allows the use of a single circuit for invasive ventilation, non-invasive ventilation (NIV), and nasal high flow (NHF). Reuse in different applications simplifies the equipment required and saves individual patients requiring numerous circuits. For example, dual-limb NIV can be performed using the same circuit, or the expiratory limb can be detached to leave the inspiratory limb for single-limb NIV and NHF.
7. COVID‑19 patients, who are critically ill with severe respiratory disease, need high levels of humidity to assist with secretion management, promote efficient ventilation and gas exchange, and to ensure optimal mucociliary function
The upper airway naturally heats and humidifies inhaled air to 37 °C and 100% Relative Humidity (44 mg/L Absolute Humidity).11,12 Invasively ventilating a patient with lower levels of heat and humidity can have the following adverse effects:
Heated humidifiers aim to deliver optimum levels of heat and humidity to patients (37 °C, 44 mg/L). HMEs achieve a maximum humidity level of 32‑33 mg/L, with many producing less than 30 mg/L.20 Using an HME provides patients with significantly lower levels of humidity than a heated humidifier, and studies show that delivering just 10% less humidity for 15 minutes can have a significant impact on mucociliary function.21
8. Heated humidifiers provide humidification without increasing instrumental dead space, an essential requirement for effective lung-protective ventilation
COVID‑19 patients require lung-protective ventilation strategies. When compared to HMEs, heated humidification may enable patients to be ventilated with reduced tidal volume (VT), reducing the partial pressure of carbon dioxide (PaCO2) and plateau pressures (Pplat), resulting in increased alveolar ventilation and gas exchange. Heated humidifiers are recommended for lung-protective ventilation,22 as reduced tidal volume delivery requires minimal instrumental dead space, which cannot be achieved with HMEs.
Lung-protective ventilation is a combination of ventilation settings and associated procedures which can have a direct impact on mortality.23–27 A key aspect of lung-protective ventilation is minimizing instrumental dead space, which can have a substantial impact on work of breathing, gas exchange, and alveolar ventilation.24,28–33 Several clinical guidelines recommend lung-protective ventilation for invasively ventilated COVID‑19 patients, or those meeting the criteria for ARDS.10,34
9. Heated humidifiers can support more effective weaning in difficult-to-wean patients compared to HMEs
COVID‑19 patients will likely be difficult to wean off mechanical ventilation due to the nature of the disease and likely development of Acute Respiratory Distress Syndrome (ARDS). Heated humidification reduces dead space and resistance to flow for optimized weaning when compared to HMEs.28
Girault et al.28 compared the use of HMEs and heated humidifiers in difficult-to-wean patients. They found that using HMEs required pressure support to be increased by 8 cmH2O in the HME group compared to the heated humidifier group. The study recommended not using HMEs in this patient group.
10. Heated humidification has no contraindications, but it is important to understand the contraindications to HME use that may present in some COVID-19 patients
There are no contraindications to the physiological conditioning of inspired gas during mechanical ventilation. However, clinicians should consider the device used to heat and humidify respiratory gases. While there are no documented contraindications for heated humidifiers, HMEs are contraindicated in some circumstances.
These include, but are not limited to:
The American Association for Respiratory Care also recommends the use of heated humidifiers over HMEs in noninvasive ventilation, as this may improve patient comfort and tolerance.22 The additional dead space and resistance added by the HME system may negate the effects of noninvasive positive pressure, elevating work of breathing and ventilatory requirements.37
Note: The simultaneous use of heated humidification and an HME should not be used as per a patient safety alert (PSA) notification issued in 2015 by the NHS and MHRA41. For further information please refer to the PSA: Risk of using different airway humidification devices simultaneously.
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment
The AIRVO 2 family enables the transition of Optiflow therapy across critical, non-critical areas of the hospital and into the home.
Humidification for patients using a mask at home
Humidification for patients with a tracheostomy at home
A flow range of 2 to 60 L/min allows for use across the care continuum - from the most acute hospital environment to the home
With Optiflow you can independently titrate flow and FiO2 according to your patient's needs
Introducing F&P Evora™ Full, our new compact full face CPAP mask. Evora Full is minimal contact with full performance featuring our next generation of Dynamic Support Technology™
The adaptable, reliable and robust humidification system. Use with Evaqua™ 2 circuit technology to minimize condensate
Updates and support for healthcare professionals
Join our global team. View and apply for jobs with us.
Get in touch with our team, find a distributor or send an enquire.